Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Obe-cel shows deep and durable responses in severe refractory lupus in Phase 1 CARLYSLE trial – Autolus

Written by | 18 Nov 2026 | Conference Highlights

Autolus Therapeutics has presented longer-term follow-up data from the Phase 1 CARLYSLE trial of obecabtagene autoleucel (obe-cel) in severe refractory systemic lupus erythematosus (srSLE) in a poster session at ACR Convergence 2026. Obe-cel is a CD19-targeting CAR T-cell therapy.

As of 11 August 2026, 15 patients had received obe-cel at a dose of 50M (eight adults and three adolescents) or 100M (four adults). Median follow-up was 19.0 months in the adult 50M cohort, 12.4 months in the adult 100M cohort and 10.1 months in the adolescent cohort, with up to 25 months of follow-up in adults. All patients had active srSLE, and 66.7% had class III or IV lupus nephritis (LN), with or without class V.

Safety

Obe-cel was well tolerated in both adults and adolescents. There were no cases of ICANS, no cases of HLH/IEC-HS and no high-grade cytokine release syndrome.

Efficacy

Despite severe disease activity at baseline, most participants had clinically significant improvements in SLEDAI-2K scores and achieved DORIS remission. This included 100% of patients followed for at least six months. Among those patients, 6 of 9 (66.7%) achieved a complete renal response at some point after infusion, and one (11.1%) achieved a partial renal response, starting at Month 7. No severe renal flares were seen.

All cohorts showed robust CAR T-cell expansion and deep B-cell depletion. When B cells returned, they were predominantly transitional or naïve. Median time to B-cell recovery was 7.2 months in the adult 50M cohort, 4.3 months in the adult 100M cohort and 6.0 months in the adolescent cohort.

“In the ongoing Phase 1 CARLYSLE trial, we continue to see deep, durable responses with obe-cel and are particularly encouraged by the continued favorable safety profile,” said Dr Matthias Will, Chief Development Officer at Autolus.

Obe-cel is now being evaluated in the Phase II LUMINA trial in patients with srSLE and active LN, at a single flat dose of 50M.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.